Pharmacology of Anticancer Drugs

  • Dwayne Dexter


It is estimated that 1.2 million new cases of cancer will be diagnosed in the United States in 2000. Although treatment advances encompassing several disciplines, including surgery, radiation treatment, and medical oncology, have reduced the mortality rate from cancer by 16% between 1950 and 1995 (excluding lung and bronchus cancer), 560,000 people per year still succumb to this disease in the United States [1]. Surgery is the best treatment for well-localized and accessible solid tumors and is often curative for many tumor types if they are detected early. However, chemotherapy remains the only alternative for tumors that have metastasized or are inaccessible to surgery or radiation. The role of chemotherapy in the success of cancer treatment regimens provides hope that further drug discoveries will have a continuing substantial impact on this disease. A thorough understanding of how current anticancer agents function in the context of tumor and cellular physiology will contribute to further rational drug discovery and improve existing regimens. This chapter reviews chemotherapeutic approaches to cancer treatment with an emphasis on drug class and mechanisms of action. The reader is referred to several excellent monographs, and the references therein, for a more detailed discussion on the pharmacology of these agents [2–7].


Breast Cancer Anticancer Drug Vinca Alkaloid Nitrogen Mustard Germ Cell Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ries LAG, Kosary CL, Hankey BF, et al, eds: SEER Cancer Statistics Review, 1973–1995. Bethesda: National Cancer Institute; 1998.Google Scholar
  2. 2.
    Grochow LB, Ames MM, eds: A Clinician’s Guide to Chemotherapy: Pharmacokinetics and Pharmacodynamics. Baltimore: Williams & Wilkins; 1998.Google Scholar
  3. 3.
    Fischer DS, Knobf MT, Durivage HJ, eds: The Cancer Chemotherapy Handbook, edn 5. St. Louis: Mosby-Year Book; 1997.Google Scholar
  4. 4.
    Teicher BA, ed: Cancer Therapeutics: Experimental and Clinical Agents. Totowa: Humana Press; 1997.Google Scholar
  5. 5.
    Perry MC, ed: The Chemotherapy Source Book, edn 2. Baltimore: Williams & Wilkins; 1996.Google Scholar
  6. 6.
    Foye WO, ed: Cancer Chemotherapy Agents. Washington, DC: American Chemical Society; 1995.Google Scholar
  7. 7.
    Pratt WB, Rudden RW, Ensminger WD, Mayburn J, eds: The Anticancer Drugs, edn 2. New York: Oxford University Press; 1994.Google Scholar
  8. 8.
    Skipper HE: Laboratory models: the historical perspective. Cancer Treat Res 1986, 70: 3–7.Google Scholar
  9. 9.
    Rosenberg B: Fundamental studies with cisplatin. Cancer 1985, 55: 2303–2316.PubMedCrossRefGoogle Scholar
  10. 10.
    Summers JB, Davidson SK: Matrix metalloproteinase inhibitors and cancer. In Annual Reports in Medicinal Chemistry, vol 33. Edited by Bristol JA. San Diego: Academic Press; 1998: 131–140.Google Scholar
  11. 11.
    Jordan MA, Wilson L: Use of drugs to study role of microtubule assembly dynamics in living cells. In Methods in Enzymology, vol 298. Edited by Vallee RB. San Diego: Academic Press; 252–276.Google Scholar
  12. 12.
    Fokman J: What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 1990, 82: 4–6.CrossRefGoogle Scholar
  13. 13.
    Folkman J, Ingber D: Inhibition of angiogenesis. Semin Cancer Bio11992, 3:89–96.Google Scholar
  14. 14.
    Balasubramanian BN, Kadow JF, Kramer RA, Vyas DM: Recent developments in cancer cytotoxics. In Annual Reports in Medicinal Chemistry, vol 33. Edited by Bristol JA. San Diego: Academic Press; 1998: 151–162.Google Scholar
  15. 15.
    Warrell RP Jr, deThé H, Wang Z-Y, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993, 329: 177–189.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine, Inc. 2000

Authors and Affiliations

  • Dwayne Dexter

There are no affiliations available

Personalised recommendations